Douglas J Watson

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis
    Douglas J Watson
    Department of Epidemiology, Merck Research Laboratories, 10 Sentry Pkwy BL1 7, Blue Bell, PA 19422, USA
    Arch Intern Med 162:1105-10. 2002
  2. ncbi request reprint Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging
    Elizabeth A Platz
    Department of Epidemiology, Room E6138, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA
    Cancer Epidemiol Biomarkers Prev 14:390-6. 2005
  3. ncbi request reprint Validation of a questionnaire to assess niacin-induced cutaneous flushing
    Josephine M Norquist
    Merck Research Laboratories, Department of Epidemiology, North Wales, PA 19454 2505, USA
    Curr Med Res Opin 23:1549-60. 2007
  4. ncbi request reprint All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database
    Douglas J Watson
    Department of Epidemiology, Biostatistics and Research Decision Sciences, Merck Research Laboratories West Point, Pennsylvania 19422, USA
    J Rheumatol 30:1196-202. 2003
  5. doi request reprint Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
    John F Paolini
    Merck Research Laboratories, Rahway, NJ, USA
    Am J Cardiol 101:625-30. 2008
  6. doi request reprint Dosage, titration, and gaps in treatment with extended release niacin in clinical practice
    Sachin J Kamal-Bahl
    Merck and Co Inc, West Point, PA, USA
    Curr Med Res Opin 24:1817-21. 2008
  7. doi request reprint Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview
    Sachin Kamal-Bahl
    Merck and Co, Inc, West Point, Pennsylvania, USA
    Clin Ther 31:130-40. 2009
  8. ncbi request reprint The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis
    Dena R Ramey
    Epidemiology, Merck Research Laboratories, West Point, PA 19486, USA
    Curr Med Res Opin 21:715-22. 2005
  9. ncbi request reprint The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis
    Douglas J Watson
    Merck Research Laboratories, West Point, PA, USA
    Curr Med Res Opin 20:1539-48. 2004
  10. ncbi request reprint Utilization patterns of cyclooxygenase-2 inhibitors among patients with arthritis in a managed care setting
    Kathleen A Foley
    Department of Epidemiology, Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania 19486, USA
    Manag Care Interface 17:21-6. 2004

Detail Information

Publications22

  1. ncbi request reprint Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis
    Douglas J Watson
    Department of Epidemiology, Merck Research Laboratories, 10 Sentry Pkwy BL1 7, Blue Bell, PA 19422, USA
    Arch Intern Med 162:1105-10. 2002
    ..Naproxen strongly inhibits platelet aggregation...
  2. ncbi request reprint Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging
    Elizabeth A Platz
    Department of Epidemiology, Room E6138, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA
    Cancer Epidemiol Biomarkers Prev 14:390-6. 2005
    ..We evaluated the association of aspirin and nonaspirin NSAIDs with subsequent prostate cancer in a prospective study. We also assessed whether use of these drugs influences serum prostate-specific antigen (PSA) concentration...
  3. ncbi request reprint Validation of a questionnaire to assess niacin-induced cutaneous flushing
    Josephine M Norquist
    Merck Research Laboratories, Department of Epidemiology, North Wales, PA 19454 2505, USA
    Curr Med Res Opin 23:1549-60. 2007
    ..To further characterize flushing, a patient-reported Flushing Symptom Questionnaire (FSQ) was developed and validated...
  4. ncbi request reprint All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database
    Douglas J Watson
    Department of Epidemiology, Biostatistics and Research Decision Sciences, Merck Research Laboratories West Point, Pennsylvania 19422, USA
    J Rheumatol 30:1196-202. 2003
    ..Much smaller elevations in risk have been found in the few community-based studies that have addressed this question...
  5. doi request reprint Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
    John F Paolini
    Merck Research Laboratories, Rahway, NJ, USA
    Am J Cardiol 101:625-30. 2008
    ..LRPT plus ERN was well tolerated. In conclusion, the significant reduction in ERN-induced flushing provided by LRPT plus ERN supports an accelerated ERN dose-advancement paradigm to achieve rapidly a 2-g dose in dyslipidemic patients...
  6. doi request reprint Dosage, titration, and gaps in treatment with extended release niacin in clinical practice
    Sachin J Kamal-Bahl
    Merck and Co Inc, West Point, PA, USA
    Curr Med Res Opin 24:1817-21. 2008
    ..To examine the dosage, titration patterns, and gaps in treatment of newly-initiated ER niacin in clinical practice...
  7. doi request reprint Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview
    Sachin Kamal-Bahl
    Merck and Co, Inc, West Point, Pennsylvania, USA
    Clin Ther 31:130-40. 2009
    ..Niacin is highly effective at raising high-density lipoprotein cholesterol but remains underused because of the adverse event of flushing...
  8. ncbi request reprint The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis
    Dena R Ramey
    Epidemiology, Merck Research Laboratories, West Point, PA 19486, USA
    Curr Med Res Opin 21:715-22. 2005
    ....
  9. ncbi request reprint The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis
    Douglas J Watson
    Merck Research Laboratories, West Point, PA, USA
    Curr Med Res Opin 20:1539-48. 2004
    ..Rofecoxib, a COX-2 specific inhibitor, was developed to provide similar efficacy and less GI toxicity than NSAIDs...
  10. ncbi request reprint Utilization patterns of cyclooxygenase-2 inhibitors among patients with arthritis in a managed care setting
    Kathleen A Foley
    Department of Epidemiology, Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania 19486, USA
    Manag Care Interface 17:21-6. 2004
    ..Given the high prevalence of arthritic conditions, these results suggest that the selection of a COX-2 inhibitor may substantially affect health care costs...
  11. ncbi request reprint Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension
    Alan Morrison
    SCRIBCO, P O Box 1525, Blue Bell, PA 19422, USA
    Curr Med Res Opin 23:2395-404. 2007
    ..To investigate the effects of continued use of non-selective NSAIDs (nsNSAIDs) on blood pressure and hypertension...
  12. ncbi request reprint Observational studies and the withdrawal of rofecoxib
    Douglas J Watson
    Department of Epidemiology, Merck Research Laboratories, West Point, PA, USA
    Pharmacoepidemiol Drug Saf 15:199-201; author reply 203-5. 2006
  13. ncbi request reprint Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review
    Paul Emery
    Rheumatology and Rehabilitation Research Unit, Research School of Medicine, University of Leeds, United Kingdom
    Clin Ther 24:1225-91. 2002
    ..However, there is a lack of consensus on dose-effect relationships with the NSAIDs...
  14. ncbi request reprint Cost-effectiveness of cyclooxygenase-2 inhibitors in chronic arthritis
    James M Pellissier
    Ann Intern Med 140:761; author reply 761-2. 2004
  15. ncbi request reprint Increase in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concern
    Douglas J Watson
    Drug Saf 30:89-90; author reply 90-1. 2007
  16. ncbi request reprint Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study
    Elham Rahme
    Department of Medicine McGill University, and Research Institute, McGill University Health Center, Montreal, Canada
    Pharmacoepidemiol Drug Saf 16:493-503. 2007
    ..To evaluate the association between rofecoxib, celecoxib, diclofenac, and ibuprofen and the risk of hospitalization for acute myocardial infarction (AMI) in an elderly population...
  17. ncbi request reprint The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events
    Richard H Hunt
    Division of Gastroenterology, McMaster University Medical Center, Hamilton, Ontario, Canada
    Am J Gastroenterol 98:1725-33. 2003
    ....
  18. ncbi request reprint An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis
    Thomas J Schnitzer
    Northwestern Center for Clinical Research, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    Clin Ther 25:3162-72. 2003
    ..This study assessed prescribing patterns for rofecoxib and celecoxib in the treatment of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as differences in prescribing patterns across physician specialties...
  19. ncbi request reprint Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications
    Priscilla Velentgas
    Ingenix i3 Drug Safety, Auburndale, MA 02466, USA
    Pharmacoepidemiol Drug Saf 15:641-52. 2006
    ..The purpose of this study was to estimate rates of acute coronary syndrome (ACS), and sudden cardiac death in relation to use of rofecoxib, celecoxib, naproxen, diclofenac, and ibuprofen...
  20. ncbi request reprint Liver function testing in patients on HMG-CoA reductase inhibitors
    Susan E Andrade
    Department of Applied Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, USA
    Pharmacoepidemiol Drug Saf 12:307-13. 2003
    ..We sought to determine the frequency and patterns of LFT screening in patients receiving HMG-CoA reductase inhibitors...
  21. ncbi request reprint Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study
    Andrew L Avins
    Kaiser Permanente Division of Research, Oakland, CA 94612, USA
    Drug Saf 31:325-34. 2008
    ..Little is known about the potential adverse hepatic effects of HMG-CoA reductase inhibitors ('statins') in patients with existing liver disease; therefore, we examined the risk of liver toxicity with lovastatin exposure in these patients...